Chardan Capital Maintains Buy on SAB Biotherapeutics, Maintains $12 Price Target
Benzinga Newsdesk 10 months ago
NewsPrice TargetAnalyst Ratings
Chardan Capital analyst Keay Nakae maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and maintains $12 price target.
Chardan Capital analyst Keay Nakae maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and maintains $12 price target.